(News Bulletin 247) – UBS reiterates its advice to buy the stock with a target price of 17.5 Swiss francs. The analyst expects a recovery, however limited, in the second half of 2023.
‘The new EBITDA guidance for FY2023 is 14% below consensus. Catalyst business is improving, UBS said.
Remember that last Friday Clariant revised downwards its sales forecasts for 2023
FY 2023 revenue is expected to be between CHF 4.55 billion and CHF 4.65 billion (compared to a previous estimate of CHF 5 billion).
Reported EBITDA for FY2023 is expected to be between CHF 650m and 700m (14.3% – 15.1% reported EBITDA margin).
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
